Biomerica (BMRA) Competitors $3.39 +0.02 (+0.56%) As of 11:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. KALA, OKUR, ESLA, BDRX, MAAQ, RANI, MRNS, SNYR, ALLK, and INKTShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include KALA BIO (KALA), OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), Biodexa Pharmaceuticals (BDRX), Mana Capital Acquisition (MAAQ), Rani Therapeutics (RANI), Marinus Pharmaceuticals (MRNS), Synergy CHC (SNYR), Allakos (ALLK), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Its Competitors KALA BIO OnKure Therapeutics Estrella Immunopharma Biodexa Pharmaceuticals Mana Capital Acquisition Rani Therapeutics Marinus Pharmaceuticals Synergy CHC Allakos MiNK Therapeutics Biomerica (NASDAQ:BMRA) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk. Is BMRA or KALA more profitable? KALA BIO has a net margin of 0.00% compared to Biomerica's net margin of -85.42%. Biomerica's return on equity of -85.90% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-85.42% -85.90% -61.06% KALA BIO N/A -369.29%-64.99% Which has better earnings & valuation, BMRA or KALA? Biomerica has higher revenue and earnings than KALA BIO. Biomerica is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.41M1.60-$5.98M-$2.32-1.46KALA BIO$3.89M10.70-$38.51M-$8.24-0.78 Does the media prefer BMRA or KALA? In the previous week, KALA BIO had 1 more articles in the media than Biomerica. MarketBeat recorded 4 mentions for KALA BIO and 3 mentions for Biomerica. Biomerica's average media sentiment score of 0.65 beat KALA BIO's score of -0.17 indicating that Biomerica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomerica 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in BMRA or KALA? 22.3% of Biomerica shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 15.0% of Biomerica shares are owned by insiders. Comparatively, 8.3% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, BMRA or KALA? Biomerica has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.88, meaning that its share price is 288% less volatile than the S&P 500. Do analysts rate BMRA or KALA? KALA BIO has a consensus target price of $13.50, suggesting a potential upside of 109.14%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBiomerica and KALA BIO tied by winning 8 of the 16 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.64M$2.43B$5.59B$9.00BDividend YieldN/A1.80%5.25%4.03%P/E Ratio-1.469.3627.5420.18Price / Sales1.60603.19415.83171.78Price / CashN/A161.3437.0657.97Price / Book1.084.658.105.61Net Income-$5.98M$31.26M$3.17B$248.59M7 Day Performance2.54%6.39%3.33%4.67%1 Month Performance-1.20%3.65%3.54%7.18%1 Year Performance1.61%2.23%33.62%21.21% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica0.39 of 5 stars$3.39+0.6%N/A-1.6%$8.64M$5.41M-1.4660KALAKALA BIO3.676 of 5 stars$5.28+3.5%$13.50+155.7%-11.4%$32.91M$3.89M-0.6430News CoverageGap UpOKUROnKure Therapeutics2.8606 of 5 stars$2.39+0.4%$32.33+1,252.9%N/A$32.15MN/A-0.45N/AESLAEstrella Immunopharma2.239 of 5 stars$0.88+0.2%$16.00+1,714.7%-22.1%$31.83MN/A-3.39N/AGap UpBDRXBiodexa PharmaceuticalsN/A$0.87+0.8%N/AN/A$31.38M$470K0.0020Upcoming EarningsMAAQMana Capital AcquisitionN/A$3.80+3.3%N/A+588.5%$30.88MN/A0.001RANIRani Therapeutics1.4904 of 5 stars$0.54+0.2%$7.33+1,267.4%-80.9%$30.78M$1.20M-0.54110Gap UpMRNSMarinus Pharmaceuticals2.3622 of 5 stars$0.55-0.2%$3.92+613.3%-56.1%$30.32M$30.99M-0.22110SNYRSynergy CHC3.2255 of 5 stars$3.37+4.0%$10.00+196.7%N/A$29.79M$34.83M0.0040ALLKAllakos3.0325 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190INKTMiNK Therapeutics2.6985 of 5 stars$7.28+0.6%$37.50+415.5%-14.4%$28.82MN/A-2.8930Gap Up Related Companies and Tools Related Companies KALA BIO Alternatives OnKure Therapeutics Alternatives Estrella Immunopharma Alternatives Biodexa Pharmaceuticals Alternatives Mana Capital Acquisition Alternatives Rani Therapeutics Alternatives Marinus Pharmaceuticals Alternatives Synergy CHC Alternatives Allakos Alternatives MiNK Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
